Vaccination with native full-length merozoite surface protein 1 (MSP1) or with recombinant C-terminal peptides protects mice against lethal challenge with virulent malaria parasites. To determine whether other regions of MSP1 can also induce protection, Plasmodium yoelii MSP1 was divided into four separate regions. Each was expressed in Escherichia coli as a fusion protein with glutathione S-transferase (GST). The Nterminal fragment began after the cleavage site for the signal sequence and ended in the region comparable to the cleavage site for the C terminus of the 82-kDa peptide of Plasmodium falciparum. This expressed protein was 30 kDa smaller than the predicted peptide. One peptide from the middle region was produced, and the C terminus consisted of a 42-kDa fragment corresponding to the analogous peptide of P. falciparum and a 19-kDa fragment that extended 37 amino acids in the amino-terminal direction beyond the probable cleavage site. To test protection of mice against lethal P. yoelii challenge, three mouse strains (CAF1, BALB/c, and A/J) were vaccinated with each of the four recombinant proteins of MSP1. Mice vaccinated with the C-terminal 19-kDa protein were highly protected (described previously), as were those vaccinated with the 42-kDa protein that contained the 19-kDa fragment. The N-terminally expressed fragment of P. yoelii was not full length because of proteolytic cleavage in E. coli. The GST-82-kDa partial fragments induced some immunity, but the surviving mice still had high parasitemias. Vaccination with the peptide from the middle region of MSP1 gave minimal to no protection. Therefore, in addition to the C-terminal 19-and 42-kDa proteins, the only other fragment to give protection was the 82-kDa protein. The protection induced by the truncated 82-kDa protein was minimal compared with that of the C-terminal fragments.
Merozoite surface protein 1 (MSP1), immunoaffinity purified from asexual blood-stage Plasmodium yoelii and Plasmodium falciparum, induces protection in mice and primates, respectively, against lethal challenge with malaria parasites (11, 16) . Subunit vaccines derived from the C terminus that include two epidermal growth factor-like domains also induce a high level of protection (4, 6, 12, 14) . Recombinant proteins that combine different regions of the protein (9, 10) and synthetic peptide vaccines that include the amino acid sequence from the N terminus (5, 15) give some protective immunity against P. falciparum in New World monkeys, but to date there has been no systematic study of subunits from different regions of MSP1. MSP1 is processed into fragments, from the N terminus to the C terminus, of 82, 28, 38, and 42 kDa (1, 2) . The C-terminal 42-kDa fragment is further cleaved to 33-and 19-kD fragments (2) . To test each region of MSP1 for induction of protective immunity, we designed recombinant DNA expression constructs of P. yoelii that approximated the known cleavage sites that are thought to occur during parasite release from the infected erythrocyte and invasion of uninfected erythrocytes. Four of the regions of MSP1 of P. yoelii (equivalent to the 82-, 28-, 42-, and 19-kDa fragments) were expressed in Escherichia coli and assessed for their ability to induce protection against a virulent infection in three strains of mice.
MATERIALS AND METHODS
Parasites. P. yoelii 17XL was kindly supplied by C. A. Long (Department of Microbiology and Immunology, Allegheny University of the Health Sciences). Infected mouse blood was stored at Ϫ70°C.
Animals. Female BALB/c, CAF1, and A/J mice, 8 to 10 weeks old, were purchased from Charles River (Wilmington, Mass.).
Recombinant construct, expression, and purification. The DNA sequence of MSP1 of P. yoelii (13) was used to estimate the cleavage fragments that correspond to those seen in MSP1 of P. falciparum (1, 15) . The gene fragments were amplified by PCR from P. yoelii DNA, restricted, and ligated into the E. coli vector pGEX3X (Pharmacia Biotech, Piscataway, N.J.). The following oligonucleotide primers were used for PCR aplification from genomic DNA of P. yoelii: the primer of MSP1[82] (sense oligonucleotide), 5Ј-GCGGATCCCTGAAACA ATTGAAGTTTATAAT-3Ј, and antisense oligonucleotide 5Ј-GCG AATTCG ATGCAGCTTGTGATGGTTGTGT-3Ј (amino acids 20 to 792 from the P. yoelii sequence reported by Lewis [13] ); the primer of MSP1[28] (sense oligonucleotide), 5Ј-GCGGATCCAAGCTGCATCATCCACA-3Ј, and antisense oligonucleotide 5Ј-GCGAATTCTCAGTATTATTTCCATCAATTTG-3Ј (amino acids 793 to 1092); the primer of MSP1[42] (sense oligonucleotide), 5Ј-GCGG ATCCAATCCGAAGATGCACCAGAA-3Ј, and antisense oligonucleotide 5Ј-G CGAATTCCAGCTGGAAGAACTACAGAA-3Ј (amino acids 1394 to 1754); and the primer of MSP1 [19] (sense oligonucleotide), 5Ј-GCGGATCCAACACATA GCCTCAATAGCT-3Ј, and the same antisense oligonucleotide as for MSP1 [42] (amino acids 1619 to 1754). Each product of PCR amplification was inserted into BamHI and EcoRI sites of the plasmid pGEX3X, creating a fusion protein with Schistosoma japonicum glutathione S-transferase (GST) and the corresponding fragment of MSP1. The MSP1 fragments ligated into the BamHI and EcoRI sites were confirmed by sequencing across the insertion sites. The DNA fragments cleaved from the BamHI/EcoRI sites were of the expected sizes.
The recombinant constructs were transformed into E. coli and induced with 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG). The bacterial cultures were grown overnight and diluted 1:10 with culture medium. The cultures were incubated for 1 h at 37°C and then induced with 1 mM IPTG for another 6 h. The bacteria were lysed by sonication, and the recombinant fusion protein was purified by affinity chromatography on glutathione-Sepharose 4B columns (Pharmacia) and eluted with 10 mM reduced glutathione (Calbiochem, San Diego, Calif.). The expressed proteins were identified by Western blot analysis with sera from mice that had been infected multiple times with P. yoelii.
Western blot analysis.
Recombinant fusion proteins were size fractionated by electrophoresis in a 4 to 20% polyacrylamide gel in the presence of sodium dodecyl sulfate and then electroblotted from the gel to a nitrocellulose membrane. The membrane was blocked with 0.2% Tween 20 in Tris-buffered saline (TBS) (200 mM NaCl, 20 mM Tris-HCl, pH 7.4) and incubated for 1 h at room temperature in the same buffer with a 1:100 dilution of rabbit anti-GST or a 1:40 dilution of mouse serum hyperimmune to P. yoelii 17XNL (nonlethal). BALB/c mice were made hyperimmune to P. yoelii by being infected intravenously four times with 10 6 infected erythrocytes at 6-week intervals, and blood was collected for serum at 2 weeks after the fourth infection. The membranes were washed four times with 0.2% Tween 20 in TBS and then incubated for 1 h with a 1:1,000 dilution of alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G (IgG) or goat anti-mouse IgG (Kirkegaard and Perry Laboratories, Gaithersburg, Md.). After a TBS wash, membranes were developed by using a stabilized substrate for alkaline phosphatase (NBT/BCIP) (Promega).
Immunization and challenge. Three mouse strains (CAF1, BALB/c, and A/J) were used. Four mice per group were inoculated subcutaneously with 60 g of each recombinant protein (
, or GST) in complete or incomplete Freund's adjuvant as follows. For primary immunization, 100 l of protein in phosphate-buffered saline (PBS) emulsified in 100 l of complete Freund's adjuvant was injected subcutaneously in four sites. All mice were boosted twice with protein in incomplete Freund's adjuvant (subcutaneously on day 21 in four sites and intraperitoneally on day 42). On day 63, mice were given a third boost intraperitoneally with 20 g of antigen alone without adjuvant. Seven to 10 days later, all mice were challenged intravenously with 10 4 lethal P. yoelii 17XL parasites. Parasitemia in challenged mice was monitored by microscopic examination of Giemsa-stained thin blood smears of tail blood fixed on glass slides with methanol. Blood smears were taken from each mouse from day 3 to 25 after infection. A negative count indicated that no parasites were detectable in 50 fields (approximately 10,000 erythrocytes).
IFA. Blood collected from mice with a 20% parasitemia was added to each well of toxoplasmosis slides (Bellco Glass, Inc., Vineland, N.J.) and fixed in dry ice-cold methanol for 15 min. The slides were then put immediately into PBS. The slides were blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at room temperature and then incubated for 1 h with sera from the mice. Sera were taken from vaccinated mice 3 days before challenge as follows. Blood (10 l) was diluted into 1 ml of 1% BSA in PBS. Sera were then further diluted 1:2, 1:4, and 1:8 in 1% BSA in PBS for the immunofluorescence assay (IFA).
After unbound primary antibody was washed off, the second antibody-either fluorescein isothiocyanate-conjugated goat anti-mouse IgG, IgG1, IgG2a, or IgG2b and IgG3 (Southern Biotechnology Associates Inc., Birmingham, Ala.)-was added to each well and left for 1 h. The washed slides were examined by fluorescence microscopy. The end point was defined as the highest serum dilution showing clear fluorescence.
RESULTS
Analysis of recombinant fusion proteins. Four recombinant MSP1 proteins fused at the amino terminus to GST from S. japonicum were expressed in E. coli ( Fig. 1 and 2) . The molecular mass of MSP1 [82] was approximately 55.5 kDa instead of the expected 85 kDa. As the GST moiety is used in the purification scheme, the reduced size was most likely the result of C-terminal truncation as a consequence of proteolysis. The recombinant GST-MSP1 [19] and GST-MSP[42] were the expected sizes as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie blue staining (Fig. 2) . The middle region was divided into two fragments for expression. Only the MSP1[28] fragment was expressed successfully and had the correct size (Fig. 2) . All recombinant , or GST alone in the same adjuvant. After vaccination with GST alone, all mice developed fulminant infections and died, with the exception of two of four mice in the CAF1 group, which survived after high parasitemia ( Fig. 3 and Table 2 ). The degrees of protection after vaccination with the four regions of MSP1 differed. GST-MSP1 [19] induced the highest level of protection in the three mouse strains (Fig. 3 and Table 2 ). This level of protection is similar to that observed in previous studies with this construct (6, 14) . GST-MSP1 [42] , which includes the sequence from MSP1[19], also induced a high level of protection. Two mice, one BALB/c and one CAF1, had higher peak parasitemias (10.7 and 4%, respectively) than those in the GST-MSP1[19] group. All CAF1 mice vaccinated with the GST-MSP1[82] recombinant protein survived and developed peak parasitemias of 6 to 40%, which were lower than the peak parasitemia (Ͼ60%) in the GST control group. Some mice in the BALB/c and A/J groups died; those that survived had peak parasitemias similar to those of the CAF1 group. Clearance of parasitemia for the survivors was at approximately day 14 ( Table 2 ). The time of clearance was in general shorter than that after vaccination with GST alone or GST-MSP1 [28] . The recombinant protein GST-MSP1
[28] induced low-level protection in the three mouse strains (Fig. 3 and Table 2 ). The comparative levels of protection for the different recombinant proteins, from highest to lowest protection, were as follows:
The parasitemia on day 3 was lowest in the most-immune mice, which were immunized with GST-MSP1 [19] , and highest in the controls, which were immunized with GST alone ( Table  2) Sera from all mice before challenge with parasites were assayed for immunoreactivity to methanol-fixed parasites by indirect IFA. Of all the IgG isotypes tested, the highest titers were those of the IgG1 isotype ( Table 1) . The different mouse strains gave similar IFA titers. There was no correlation between titers and protection.
DISCUSSION
MSP1 is a 190-to 230-kDa (depending on the Plasmodium sp.) surface protein on merozoites that is processed into smaller fragments prior to or at the time of merozoite invasion into erythrocytes (1, 2, 8) . The interest in this molecule as a vaccine candidate developed from the high level of protection induced by immunization with affinity-purified protein, first against P. yoelii in mice (11) and later against P. falciparum in Aotus monkeys (16) . Synthetic and recombinant peptides from different regions of MSP1 were used to immunize mice against P. yoelii and monkeys against P. falciparum. The recombinant 19-kDa C termini from both P. falciparum in Aotus and P. yoelii in mice induced protection after immunization with Freund's adjuvant (6, 14) . A 42-kDa C-terminal protein that contained the 19-kDa peptide also induced partial protection against P. falciparum (4). Immunization with other synthetic and recombinant peptides from portions of the N-terminal 82-kDa fragment of MSP1 of P. falciparum induced partial protection in some monkeys; others died despite immunization (9, 10) .
In the present study, we systematically studied recombinant peptides from the 230-kDa protein of P. yoelii. The 19-kDa C-terminal peptide gave a high level of protection, as has been described in previous studies. The 42-kDa peptide that contains the 19-kDa peptide also was highly protective, giving (7, 17) . It is interesting that the C-terminal peptides of P. yoelii expressed in bacteria were effective, whereas only the yeast and baculovirus products worked against P. falciparum in monkeys (3). Two differences between them are that the P. yoelii peptide contained 37 amino acids that are N terminal to the predicted cleavage site and that the P. yoelii peptide contained 10, not 12, cysteines. The 82-kDa N terminus was partially degraded; only a minor fraction appeared to be full length. This peptide gave partial protection despite high parasitemia after challenge in vaccinated mice. The clearance of parasitemia was earlier than that in the control group and in the MSP1[28]-immunized mice that survived. The level of protection was similar to those observed in studies using peptides or recombinant proteins from a portion of the N terminus of the 82-kDa peptide (9, 10) . The recombinant peptide from the region of P. yoelii between the N terminus and the C terminus gave minimal to no detectable protection. It is possible that the recombinant proteins (MSP1 [28] and MSP1[82]) did not reflect the structure of the native protein and, therefore, that antibody to critical epitopes on the parasite may not have been induced. In addition, other regions (e.g., a fragment from the C terminus of the 82-kDa protein fused to a peptide in the middle region) may induce protection.
This study depended on Freund's complete adjuvant for induction of protection. It may be possible, through combining the 82-kDa N terminus and the 19-kDa C terminus, to induce protection without the requirement for Freund's adjuvant. Our study and those of others indicate that the 82-kDa N terminus should be further studied.
